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Muscular dystrophy meets protein biochemistry,
the mother of invention
Steven D. Funk and Jeffrey H. Miner
Department of Medicine, Division of Nephrology, Washington University School of Medicine, St. Louis, Missouri, USA.

Muscular dystrophies result from a defect in the linkage between the muscle
fiber cytoskeleton and the basement membrane (BM). Congenital muscular
dystrophy type MDC1A is caused by mutations in laminin α2 that either
reduce its expression or impair its ability to polymerize within the muscle
fiber BM. Defects in this BM lead to muscle fiber damage from the force
of contraction. In this issue of the JCI, McKee and colleagues use a laminin
polymerization–competent, designer chimeric BM protein in vivo to restore
function of a polymerization-defective laminin, leading to normalized
muscle structure and strength in a mouse model of MDC1A. Delivery of such
a protein to patients could ameliorate many aspects of their disease.

Many pathways to muscular
dystrophy

The mechanism whereby a contractile multinucleated skeletal muscle fiber is linked
to the basement membrane (BM) that
ensheaths it represents a paradigm for our
understanding of BM assembly and interactions between the cell and extracellular
matrix in the context of human pathobiology. Multiple matrix proteins, cell-surface
receptors, transmembrane accessory proteins, cytoskeletal linker proteins, and glycosylating enzymes are required for the
establishment and maintenance of the large,
integrated complex that tightly links the
myofiber cytoskeleton to the sarcolemma
(plasma membrane) and the sarcolemma to
the skeletal muscle BM (1). Genetic defects
that alter the expression, structure, or function of these proteins cause a devastating
class of diseases, the muscular dystrophies.
Muscular dystrophies are characterized
by the progressive degeneration and weakness of skeletal muscle that includes muscle
fiber necrosis, regeneration, and fibrosis
(2). The severity and rate of progression of
muscular dystrophy can vary dramatically,
from congenital forms to the more common
delayed-onset form known as Duchenne

muscular dystrophy (3). From a cell biological perspective, muscular dystrophies with
a genetic basis can be divided into types that
correspond roughly to the site of the protein
or protein complex that is affected by mutation. Mutations that affect the muscle BM
cause congenital muscular dystrophy; those
that affect the cytoskeletal protein dystrophin cause Duchenne and Becker muscular
dystrophy; and those that affect transmembrane proteins called sarcoglycans cause
limb-girdle muscular dystrophy (3). Interestingly, mutations that impact the enzymes
responsible for glycosylation of dystroglycan cause the dystroglycanopathies, which
manifest as muscular dystrophies with variable degrees of severity and timing of onset,
as well as variable CNS and eye defects
(4). Dystroglycan serves as the functional
centerpiece of the dystrophin-glycoprotein
complex that links the cytoskeleton to the
BM and, therefore, plays a crucial role in
maintaining skeletal muscle health (5).

Laminin and the basement
membrane

Like all BMs, the skeletal muscle fiber BM
contains specific isoforms from four major
matrix protein families: laminins, type IV
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collagens, nidogens, and heparan sulfate
proteoglycans. Laminins are large heterotrimeric glycoproteins composed of one
α, one β, and one γ chain (6). The major
laminin isoform of skeletal muscle BM
is laminin α2β1γ1 (Lm211; Figure 1, left),
while a structurally and functionally different isoform, laminin α5β2γ1, is found at
the neuromuscular junction (7). Lm211 is
a cruciform macromolecule that can selfpolymerize in vitro to form a network via
the formation of intermolecular ternary
complexes involving the laminin N-terminal (LN) domain of each of the three chains
(8). The unique C-terminus of the α2 chain,
called the laminin globular (LG) domain,
binds to receptors on the surface of the
myofiber, including α-dystroglycan and
integrin α7β1 (1). The binding of laminin
to its receptors as muscle forms is thought
to have a dual purpose: a) initiation of BM
formation by concentrating the laminin at
the cell surface above a critical concentration that promotes polymerization; and b)
sending a signal to the cell (9). Upon maturation, laminin binding to its receptors
links the muscle fiber to the BM, into which
the laminin has become deeply integrated
via direct and indirect interactions with
nidogen, collagen IV, and proteoglycans.
Mutations in the laminin α2–encoding
gene (LAMA2) cause congenital muscular
dystrophy. Mutations that prevent production of the protein typically (though not
always) cause more severe disease than do
missense mutations, internal deletions, or
mutations that reduce Lm211 protein levels (1) (Figure 1, middle). The existence of
several naturally occurring and engineered
mouse models with Lama2 mutations with
features of human congenital muscular dystrophy have been instrumental for investigating pathogenic mechanisms and potential treatments for both severe and milder
forms of the disease (10).

Biochemistry and protein therapy

The current work by McKee et al. in this
issue (11) and previous studies have exploit-
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Figure 1. A designer chimeric polypeptide restores function of defective laminin. Lm211 is a heterotrimeric glycoprotein consisting of one α2-, one β1-, and one γ1-subunit that is an essential extracellular matrix component of the skeletal muscle fiber BM. WT Lm211 readily polymerizes and becomes
integrated into the BM and serves to link the muscle fiber to the BM via receptor binding. Mutations
in the gene encoding the laminin α2-subunit cause a congenital muscular dystrophy due to absent or
defective Lm211. The mutant Lm211 present in dy2J/dy2J mice has a truncated laminin α2 that is unable
to polymerize. The polymerization defect results in disruption of the BM, leading to loss of BM integrity and reduced muscle function. In this issue, McKee and colleagues developed a chimeric polypeptide
(αLNNd) that contains the laminin N-terminal (LN) domain of the laminin α1-subunit and the G2-G3
domains of nidogen, which simultaneously rescued polymerization of mutant truncated laminin α2/
Lm211 (right) and linked laminin to the collagen IV network (not depicted). αLNNd thereby restored
muscle function in dy2J/dy2J mice.

ed the intermolecular interactions among
BM proteins and their cognate receptors
that have been deciphered through decades
of basic science research. In addition to
laminin-receptor interactions, laminins are
secondarily and indirectly linked to cellsurface receptors by the heparan sulfate
proteoglycan agrin, which binds to the LMγ1
coiled-coil region via its N-terminal agrin
domain as well as to dystroglycan and integrins via its C-terminal LG-like domains
(12). Furthermore, the laminin network is
linked to the type IV collagen network by
nidogen, which binds to the short arm LE3b
segment of LMγ1 via nidogen’s G3 domain
and to a region in collagen IV near the Cterminal noncollagenous 1 (NC1) domain
via nidogen’s G2 domain (13).
Previously, research teams led by Ruegg
tested a molecular therapy in severe forms
of congenital muscular dystrophy, in which

LMα2 is either truncated and expressed at
very low levels (dyw/dyw mice) or completely missing (dy3K/dy3K mice). These mice and
patients who lack LMα2 exhibit increased
LMα4- and LMα5-containing trimers,
but decreased α-dystroglycan expression.
Although these laminins have poor musclespecific receptor binding, and LMα4 lacks
the LN domain required for polymerization, Ruegg and colleagues hypothesized
that a mini-agrin protein containing only
the laminin- and dystroglycan-binding
domains might both stabilize the laminin
network and restore dystroglycan levels.
Collectively, dy3K/ dy3K and dyw/dyw mice
expressing mini-agrin in skeletal muscle via
a transgene exhibited a marked increase in
muscle function and lifespan and improved
BM morphology, with increased incorporation of the polymerization-capable LMα5.
In this scenario, mini-agrin links the lami-

nin network, albeit an aberrant network,
to dystroglycan, which is likely the major
mechanism of disease attenuation (14, 15).
Patients who harbor mutations that
only affect the LMα2 LN domain have
mild phenotypes compared with those
with mutations that result in total loss of
LMα2 (16), similar to missense mutations
in the LMβ2 LN domain that affect the kidney glomerular BM of Pierson syndrome
spectrum patients (17). On the basis of biochemical studies, LN domain mutations in
LMβ2 and LMα2 are predicted to confer
some degree of laminin polymerization
defects. For LMα2, these are collectively modeled by dy2J/dy2J mice that lack the
LMα2 LN domain; but, unlike dyw/dyw
mice, dy2J/dy2J mice show only a modest
decrease in LMα2 protein levels. McKee et
al. exploited the laminin-nidogen-collagen
linkage to explore the therapeutic efficacy
of a chimeric fusion protein, αLNNd, via
transgenic expression in skeletal muscle of
dy2J/dy2J mice.
The αLNNd protein is composed of
the LMα1 LN and LEa1-4 domains fused
to the G2-G3 portions of nidogen, thereby replacing the nidogen G1 domain and
short segment that connects G1 to the
G2-G3 segment with the LMα1 N-terminus. The nidogen portion binds to LMγ1
LE3b via the G3 domain and to the collagen type IV network via the G2 domain,
thereby preserving the laminin-collagen
linkage. Biochemical studies and naturally existing laminin heterotrimer combinations (Lm111, Lm211) prove that both
LMα1 and LMα2 LN domains facilitate
polymerization through interactions with
LMβ1 and LMγ1 LN domains. Additionally, both overexpression and exogenous
provision of Lm111 can ameliorate muscular dystrophy in Lama2-mutant mice (18,
19). Thus, the LMα1 LN domain of αLNNd
readily substitutes for the missing LMα2
LN domain both in vivo and in vitro (11).
This chimeric protein corrects the polymerization defect in dy2J/dy2J mice (Figure
1, right) (and should presumably do the
same in LMα2 polymerization–defective
patients), thereby reinforcing the concept
that laminin polymerization is critical for
maintaining BM integrity. Moreover, like
the effects of the mini-agrin protein in the
dyw/dyw and dy3K/dy3K models, the αLNNd
chimera restored muscle performance in
dy2J/dy2J animals to a level similar to that
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of control animals and normalized most
histopathological parameters. αLNNd
also normalized mutant LMα2 and LMγ1
protein levels in vivo to those of control
mice and restored polymerization of the
mutant Lm211 on the surface of cultured
cells, indicating that the fusion protein
behaved as predicted.

Prospects for the future

There are currently no effective treatments
for muscular dystrophies. Experimental
studies reveal that pharmaceutical modulation of some basic physiological and cell
biological processes, including inflammation, fibrosis, apoptosis, and regeneration,
may improve patients’ phenotypes (1).
In parallel, we summarize here exciting,
basic science–driven molecular modulations that address the matrix protein deficiencies underlying congenital muscular
dystrophies. Although McKee et al. did
not investigate inducible rescue with αLNNd, which would better mimic attempted
therapy in a clinical context, the efficacy of
induced expression of mini-agrin (20) indicates that dy2J/dy2J phenotypes would likely
be improved by late therapeutic intervention. In addition, Qiao et al. demonstrated
that expression of a mini-agrin cDNA packaged into an adeno-associated virus that
can either be directly injected into muscles or delivered systemically improves
phenotypes in mice (21). Interestingly,
αLNNd did not interfere with WT Lm111
polymerization in assays on myotubes in
vitro (11), suggesting that this fusion protein does not perturb normal BM integrity
in vivo. We would further suggest that the
combination of mini-agrin and αLNNd
may have synergistic effects by enhancing
dystroglycan binding of an αLNNd-stabilized LMα4 network, the most highly compensating laminin in patients and mice
lacking LMα2. The study by Mckee et al.
indicates that functional designer molecules, potentially in combination with suit-
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able delivery systems and pharmaceutical
strategies (1), hold promise as future therapeutics for congenital muscular dystrophy.
Importantly, the small sizes of αLNNd (157
kDa) and mini-agrin (106 kDa) relative
to the affected 341-kDa LMα2 chain and
the approximately 750-kDa Lm211 trimer, together with the fact that αLNNd and
mini-agrin function as monomers, make
them well suited for therapeutic intervention, whether delivered as naked or virally
encoded proteins.
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